Value investors are well aware that investing in technology companies is not an easy task. Additionally, valuing bio-tech companies is far more difficult. The Manual of Ideas conducted an interview with Humphrey Nokes of Cygna Negra, on this very topic. Nokes discusses how value investors can evaluate bio-tech companies in this video interview:
'Get ValueWalk's Daily Edition By Email and Never Miss Our Top Stories' 
